Furthermore, changes in the sulfation pattern of PNNs’ chondroitin sulfate-glycosaminoglycan (CS-GAG) have been linked to p-Tau accumulation and pathology progression in AD patients, suggesting that this could be an early hallmark of the disease (Figure 3a) [213]. This evidence concerns the gene MAPT and Alzheimer disease.